Eduardo de Marchena, MD
Interventional Cardiology · Miami, FLNPI 1801824339
Payments from drug & device makers
What this record shows
This record is dominated by other: $489,351 of the $498,148 with a category attached, or 98.2%. Tendyne Holdings, Inc. accounts for 98.2% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $490,408, more than ten times the $421 reported in 2019. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $4049.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tendyne Holdings, Inc.$489K
- Abbott$4K
- Boston Scientific$2K
- Medtronic$1K
- Inari Medical, Inc.$890
- Edwards Lifesciences$439
- plus $1K from 10 others
Across 42 payments — averaging $11,420 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$480K
What the payments were for
- Travel & lodging$8400%
- Food & beverage$7,9572%
- Other$489,35198%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tendyne Holdings, Inc. | 1 | $489,069 |
| Abbott | 46 | $3,851 |
| Boston Scientific | 27 | $1,557 |
| Medtronic(2 entities) | 14 | $1,255 |
| Inari Medical, Inc. | 8 | $890 |
| Edwards Lifesciences | 4 | $439 |
| Shockwave Medical, Inc | 6 | $323 |
| Penumbra, Inc. | 2 | $291 |
| Cardiva Medical, Inc. | 6 | $205 |
| Ablative Solutions, Inc. | 1 | $121 |
| Biosense Webster, Inc. | 2 | $48 |
| Johnson & Johnson | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| AstraZeneca | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Asahi Intecc USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$1,474
- FLOWTRIEVER CATHETER, S$735
- CT THROMBECTOMY SYSTEM KIT$735
- COREVALVE EVOLUT R$494
- GENERAL - THERAPIES$363
- Indigo System$291
- MitraClip$283
- PORTICO$282
- Trifecta GT Tissue Heart Valve$263
- WATCHMAN Access System$247
- Vascular Lithotripsy$237
- EVOQUE$213
- NAVITOR$159
- AMPLATZER$147
- CoreValve Evolut$144
- Quadra Assura CRT Defibrillator$139
- DRAGONFLY OPSTAR$114
- AVEIR$114
- Sentinel$112
- AVVIGO Guidance System$112
How this compares
$498,148 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 13 | $108,548 |
| EliquisApixaban | 25 | $24,934 |
| EntrestoSacubitril/Valsartan | 17 | $18,295 |
| Candesartan Cilexetil | 14 | $1,448 |
| Metoprolol Succinate | 50 | $835 |
| Losartan Potassium | 44 | $715 |
| Rosuvastatin Calcium | 56 | $587 |
| ClopidogrelClopidogrel Bisulfate | 52 | $518 |
| Furosemide | 29 | $192 |
| Amlodipine Besylate | 21 | $151 |
| Carvedilol | 13 | $106 |
| Hydrochlorothiazide | 19 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $15 | $108,54813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Juan ZambranoMiami$173K
- Michael DyalMiami$157K
- Nish PatelMiami$149K
- Pedro Martinez-ClarkMiami$136K
- Mauricio CohenMiami$129K
- Marquand PattonMiami$112K
- Ramon QuesadaMiami$94K
- Alvaro GomezMiami$71K
- Vinod ChainaniMiami$69K
- Arthur LeeGainesville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.